Drug Guide
Carvedilol
Classification
Therapeutic: Antihypertensive, Heart failure agent
Pharmacological: Non-selective beta-adrenergic blocker with alpha-1 blocking activity
FDA Approved Indications
- Hypertension
- Heart failure with reduced ejection fraction
- Left ventricular dysfunction after myocardial infarction
Mechanism of Action
Carvedilol blocks both beta-adrenergic receptors and alpha-1 adrenergic receptors, leading to decreased heart rate, myocardial contractility, and vasodilation, which collectively lower blood pressure and reduce cardiac workload.
Dosage and Administration
Adult: Typically start with 6.25 mg twice daily, titrate based on response and tolerability. Maintenance doses range from 12.5 to 25 mg twice daily.
Pediatric: Safety and efficacy not established; use in children is not routinely recommended.
Geriatric: Initiate at lower doses due to increased sensitivity and potential for side effects.
Renal Impairment: May require dosage adjustment; monitor renal function regularly.
Hepatic Impairment: Start at lower doses; monitor liver function as needed.
Pharmacokinetics
Absorption: Well absorbed orally, with extensive first-pass metabolism.
Distribution: Widely distributed in tissues; highly bound to plasma proteins.
Metabolism: Primarily metabolized in the liver via CYP2D6 and CYP3A4 enzymes.
Excretion: Excreted mainly via feces; small amounts in urine.
Half Life: Approximately 7 to 10 hours, allowing for twice-daily dosing.
Contraindications
- Asthma or bronchospastic disease
- Salty or sinus bradycardia
- Heart block greater than first degree without pacemaker
- Sick sinus syndrome
Precautions
- Use with caution in diabetes mellitus (may mask hypoglycemia symptoms), peripheral vascular disease, and hepatic impairment. Monitor for signs of heart failure.
Adverse Reactions - Common
- Dizziness (Common)
- Fatigue (Common)
- Hypotension (Common)
- Weight gain (Less common)
Adverse Reactions - Serious
- Bradycardia (Uncommon)
- Heart failure worsening (Uncommon)
- Bronchospasm (Rare)
- Liver enzyme elevation (Rare)
Drug-Drug Interactions
- Other antihypertensives, especially calcium channel blockers like verapamil or diltiazem
- Insulin and oral hypoglycemics (may enhance hypoglycemia)
- Clonidine
Drug-Food Interactions
N/ADrug-Herb Interactions
N/ANursing Implications
Assessment: Monitor blood pressure, heart rate, signs of heart failure, and blood glucose levels as appropriate.
Diagnoses:
- Ineffective tissue perfusion
- Risk for falls due to dizziness
- Impaired cardiac output
Implementation: Administer with food to minimize orthostatic hypotension. Titrate doses gradually. Educate patients on daily blood pressure and heart rate monitoring.
Evaluation: Assess therapeutic response and side effects; adjust dose accordingly.
Patient/Family Teaching
- Do not discontinue abruptly to avoid rebound hypertension.
- Take medication with food to reduce orthostatic hypotension.
- Report signs of dizziness, shortness of breath, or worsening heart failure.
- Monitor blood pressure regularly.
Special Considerations
Black Box Warnings:
- None specific to carvedilol, but caution with heart failure and in diabetic patients due to masking hypoglycemia symptoms.
Genetic Factors: Variable metabolism via CYP2D6; poor metabolizers may have increased drug levels.
Lab Test Interference: May alter liver function tests.
Overdose Management
Signs/Symptoms: Severe hypotension, bradycardia, heart failure, bronchospasm.
Treatment: Supportive care, including IV fluids for hypotension, atropine for bradycardia, and vasopressors if needed. Do not induce vomiting.
Storage and Handling
Storage: Store at room temperature, away from moisture and light.
Stability: Stable until expiration date on packaging.